CTNM
$13.21
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-7...
Recent News
Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference
Executives from Contineum Therapeutics (NASDAQ:CTNM) outlined the company’s clinical priorities and upcoming catalysts during a presentation at the Leerink Global Healthcare Conference, emphasizing a shift from a discovery platform to a clinical-stage company with two lead programs and multiple tria
Beat the Market the Zacks Way: Contineum Therapeutics, Suzano, PepsiCo in Focus
Contineum Therapeutics surged 27% after a Zacks Rank upgrade, spotlighting how Zacks' strategies are beating a volatile market.
Is Contineum Therapeutics, Inc. (CTNM) Stock Outpacing Its Medical Peers This Year?
Here is how Contineum Therapeutics, Inc. (CTNM) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.
Contineum Therapeutics, Inc. (NASDAQ:CTNM) surges 10%; retail investors who own 51% shares profited along with institutions
Key Insights Contineum Therapeutics' significant retail investors ownership suggests that the key decisions are...
Contineum Therapeutics, Inc. (CTNM) Upgraded to Buy: What Does It Mean for the Stock?
Contineum Therapeutics, Inc. (CTNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).